concept · intermediate · partly written
RNA interference
RNA interference is the cell machinery in which a short RNA guide strand finds a matching messenger RNA and causes it to be cut, which is the mechanism siRNA medicines borrow.
Also called: RNAi, RISC
RNAi in brief
A short double-stranded RNA is taken up by a protein complex called RISC. One strand is kept as a guide; it pairs with a matching messenger RNA and the complex cuts that message so the protein is not made. 12
Reported, not yet replicated
What was shown more
In 2001 duplexes of 21 nucleotides were shown to silence genes in cultured human cell lines (abstract only read here). A 2003 study of the silencing complex reported that the two ends of the duplex are not equal and that this asymmetry decides which strand the complex keeps (abstract only). Both underlie the design of the guide strand of an siRNA drug. 12
Reported, not yet replicated
Why lowering the target is not the same as benefit more
Two siRNAs against the same liver protein, transthyretin, had opposite outcomes. Patisiran improved the neuropathy score in the APOLLO trial. Revusiran was stopped when on-treatment deaths were 18 of 140 treated against 2 of 66 on placebo, and the authors state that no clear causative mechanism was identified. Knockdown of the target shows the mechanism working, not that the patient benefits. 34
Reported, not yet replicated
Plain answer
Why it matters
Real numbers
APOLLO
225 patients; the neuropathy score mNIS+7 changed by about -6.0 on patisiran against +28.0 on placebo (abstract). 3
Reported, not yet replicated
ENDEAVOUR
On-treatment deaths 18 of 140 on revusiran against 2 of 66 on placebo (abstract). 4
Reported, not yet replicated
Teach this
In one sentence
A cell pathway that cuts a message matching a guide RNA, used by siRNA drugs. 1
Reported, not yet replicated
The five-minute version
A double-stranded RNA is loaded into RISC; one strand is kept as a guide and pairs with a matching message, which is cut. The drug is the guide, so its target is chosen by sequence, and the difficulty is getting it into cells. 1
Reported, not yet replicated
What a listener will ask
Does it edit the gene?
No; it acts on the RNA message and the gene is unchanged.
Is it the same as an antisense oligo?
Both act on RNA but with different machinery; see modalities/antisense-oligonucleotide.
Does lowering the target mean the drug works?
No; see the APOLLO and ENDEAVOUR pair.
The common wrong idea
Silencing a gene with siRNA is the same as treating the disease.
Knockdown shows the mechanism works; benefit has to be shown in patients, and two drugs with the same target had opposite outcomes.
The one citation to hand over: 1
Still open here
- Why did revusiran increase deaths? The ENDEAVOUR authors found no clear causative mechanism.
- How exactly does a GalNAc-conjugated siRNA leave the endosome? Not settled in the sources opened here.
Not yet written: Equation.
Linked from
Sources
- Elbashir SM, et al.. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001). paper; opened 2026-11-17 all records citing this
- Schwarz DS, et al.. Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003). paper; opened 2026-11-17 all records citing this
- Adams D, et al.. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med (2018). paper; opened 2026-11-17 all records citing this
- Judge DP, et al.. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther (2020). paper; opened 2026-11-17 all records citing this
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/concepts/rna-interference.json